Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast12
jRCT2031210182Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 4, open-label trial of trastuzumab deruxtecan in breast cancer (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate and Progression-free survival. Started Aug 2021; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031210182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210182.